Aspira Pathlab & Diagnostics Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: July 26, 2025, 1:55 pm

Market Cap	65.9 Cr.
Current Price	64.0
High / Low	107/29.2
Stock P/E	31.8
Book Value	11.9
Dividend Yield	0.00 %
ROCE	17.2 %
ROE	23.8 %
Face Value	10.0
PEG Ratio	3.76

Quick Insight

Aspira Pathlab & Diagnostics Ltd, trading at ₹57.9 with a market cap of ₹59.6 crore, showcases a price-to-earnings (P/E) ratio of 28.8, indicating a relatively high valuation compared to its net profit of ₹2.07 crore. The company's return on equity (ROE) stands at 23.8%, reflecting efficient use of shareholder funds, while a return on capital employed (ROCE) of 17.2% suggests solid operational performance. However, with a price-to-book value (P/BV) ratio of 7.21x, the stock may be considered overvalued. The low borrowing level of ₹3.20 crore against reserves of ₹1.92 crore provides a cushion, but the high promoter ownership of 18.55% and a public holding of 81.46% indicate potential volatility in shareholder sentiment. In conclusion, while Aspira’s strong profitability metrics are encouraging, investors should be

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Aspira Pathlab & Diagnostics Ltd

Competitors of Aspira Pathlab & Diagnostics Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
NG Industries Ltd	52.3 Cr.	156	206/145	6.75	115	2.24 %	23.6 %	20.7 %	10.0
Global Longlife Hospital and Research Ltd	27.5 Cr.	26.2	46.4/18.3	137	25.5	0.00 %	1.16 %	0.76 %	10.0
Gian Lifecare Ltd	16.0 Cr.	15.4	27.0/12.1	5.64	19.2	0.00 %	29.2 %	24.6 %	10.0
Fortis Malar Hospitals Ltd	129 Cr.	68.8	98.7/51.0	331	16.1	61.8 %	0.83 %	0.56 %	10.0
Family Care Hospitals Ltd	23.6 Cr.	4.36	9.50/3.40	0.77	2.49	0.00 %	77.2 %	84.8 %	10.0
Industry Average	27,692.50 Cr	821.00		125.77	95.59	3.02%	16.02%	14.76%	9.04

All Competitor Stocks of Aspira Pathlab & Diagnostics Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	5.44	2.97	3.71	4.37	3.41	2.60	3.32	3.46	3.82	4.64	6.18	5.41	5.78
Expenses	3.38	2.79	3.25	3.56	3.26	2.92	3.68	3.83	3.95	4.29	4.83	4.65	4.73
Operating Profit	2.06	0.18	0.46	0.81	0.15	-0.32	-0.36	-0.37	-0.13	0.35	1.35	0.76	1.05
OPM %	37.87%	6.06%	12.40%	18.54%	4.40%	-12.31%	-10.84%	-10.69%	-3.40%	7.54%	21.84%	14.05%	18.17%
Other Income	0.04	0.06	0.07	0.12	0.07	0.10	0.14	0.10	0.08	0.09	0.08	0.09	0.13
Interest	0.15	0.11	0.11	0.10	0.10	0.10	0.10	0.09	0.08	0.08	0.08	0.09	0.09
Depreciation	0.51	0.42	0.40	0.39	0.38	0.39	0.39	0.38	0.38	0.38	0.36	0.39	0.37
Profit before tax	1.44	-0.29	0.02	0.44	-0.26	-0.71	-0.71	-0.74	-0.51	-0.02	0.99	0.37	0.72
Tax %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Profit	1.44	-0.29	0.02	0.44	-0.26	-0.72	-0.71	-0.74	-0.50	-0.02	0.99	0.38	0.72
EPS in Rs	1.40	-0.28	0.02	0.43	-0.25	-0.70	-0.69	-0.72	-0.49	-0.02	0.96	0.37	0.70

Last Updated: May 31, 2025, 6:53 am

Below is a detailed analysis of the quarterly data for Aspira Pathlab & Diagnostics Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 5.78 Cr.. The value appears strong and on an upward trend. It has increased from 5.41 Cr. (Dec 2024) to 5.78 Cr., marking an increase of 0.37 Cr..
For Expenses, as of Mar 2025, the value is 4.73 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.65 Cr. (Dec 2024) to 4.73 Cr., marking an increase of 0.08 Cr..
For Operating Profit, as of Mar 2025, the value is 1.05 Cr.. The value appears strong and on an upward trend. It has increased from 0.76 Cr. (Dec 2024) to 1.05 Cr., marking an increase of 0.29 Cr..
For OPM %, as of Mar 2025, the value is 18.17%. The value appears strong and on an upward trend. It has increased from 14.05% (Dec 2024) to 18.17%, marking an increase of 4.12%.
For Other Income, as of Mar 2025, the value is 0.13 Cr.. The value appears strong and on an upward trend. It has increased from 0.09 Cr. (Dec 2024) to 0.13 Cr., marking an increase of 0.04 Cr..
For Interest, as of Mar 2025, the value is 0.09 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.09 Cr..
For Depreciation, as of Mar 2025, the value is 0.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.39 Cr. (Dec 2024) to 0.37 Cr., marking a decrease of 0.02 Cr..
For Profit before tax, as of Mar 2025, the value is 0.72 Cr.. The value appears strong and on an upward trend. It has increased from 0.37 Cr. (Dec 2024) to 0.72 Cr., marking an increase of 0.35 Cr..
For Tax %, as of Mar 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00%.
For Net Profit, as of Mar 2025, the value is 0.72 Cr.. The value appears strong and on an upward trend. It has increased from 0.38 Cr. (Dec 2024) to 0.72 Cr., marking an increase of 0.34 Cr..
For EPS in Rs, as of Mar 2025, the value is 0.70. The value appears strong and on an upward trend. It has increased from 0.37 (Dec 2024) to 0.70, marking an increase of 0.33.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 2:49 pm

Metric	Mar 2012	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	0.00	0.00	0.00	0.76	4.36	7.64	8.42	15.21	19.54	14.46	13.20	22.00
Expenses	0.02	0.14	0.23	3.34	8.24	10.88	10.25	11.69	13.16	12.86	14.38	18.47
Operating Profit	-0.02	-0.14	-0.23	-2.58	-3.88	-3.24	-1.83	3.52	6.38	1.60	-1.18	3.53
OPM %				-339.47%	-88.99%	-42.41%	-21.73%	23.14%	32.65%	11.07%	-8.94%	16.05%
Other Income	0.02	0.21	0.32	0.31	0.22	0.25	0.29	0.20	0.09	0.32	0.42	0.39
Interest	0.00	0.00	0.05	0.26	0.80	0.96	1.01	0.89	0.37	0.42	0.37	0.35
Depreciation	0.00	0.00	0.00	0.20	1.12	1.23	1.66	1.44	1.64	1.59	1.54	1.49
Profit before tax	0.00	0.07	0.04	-2.73	-5.58	-5.18	-4.21	1.39	4.46	-0.09	-2.67	2.08
Tax %		57.14%	25.00%	0.00%	0.00%	0.00%	0.71%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Profit	0.00	0.02	0.03	-2.72	-5.58	-5.18	-4.24	1.38	4.46	-0.09	-2.67	2.07
EPS in Rs	0.00	0.09	0.13	-5.24	-10.75	-6.32	-4.56	1.34	4.33	-0.09	-2.59	2.01
Dividend Payout %		0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	50.00%	-9166.67%	-105.15%	7.17%	18.15%	132.55%	223.19%	-102.02%	-2866.67%	177.53%
Change in YoY Net Profit Growth (%)	0.00%	-9216.67%	9061.52%	112.32%	10.98%	114.40%	90.64%	-325.21%	-2764.65%	3044.19%

Aspira Pathlab & Diagnostics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	21%
3 Years:	4%
TTM:	67%

Compounded Profit Growth
10 Years:	59%
5 Years:	20%
3 Years:	-23%
TTM:	178%

Stock Price CAGR
10 Years:	%
5 Years:	25%
3 Years:	7%
1 Year:	104%

Return on Equity
10 Years:	%
5 Years:	17%
3 Years:	-3%
Last Year:	24%

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:48 pm

Month	Mar 2012	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	0.40	2.25	2.25	5.19	5.19	8.19	9.29	10.29	10.29	10.29	10.29	10.29
Reserves	0.19	1.36	1.39	0.72	-4.86	-7.93	-10.42	-6.91	-2.43	-2.47	-5.08	1.92
Borrowings	0.00	0.00	2.62	7.29	11.36	12.52	13.80	7.01	8.85	8.24	7.71	3.20
Other Liabilities	0.03	0.21	0.03	1.66	0.84	2.02	1.67	1.39	1.42	1.28	1.79	2.10
Total Liabilities	0.62	3.82	6.29	14.86	12.53	14.80	14.34	11.78	18.13	17.34	14.71	17.51
Fixed Assets	0.00	0.00	0.04	7.79	7.91	8.90	8.70	7.75	9.57	8.01	6.79	6.53
CWIP	0.00	0.00	0.00	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.13
Other Assets	0.62	3.82	6.25	6.82	4.62	5.90	5.64	4.03	8.56	9.33	7.92	10.85
Total Assets	0.62	3.82	6.29	14.86	12.53	14.80	14.34	11.78	18.13	17.34	14.71	17.51

Below is a detailed analysis of the balance sheet data for Aspira Pathlab & Diagnostics Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 10.29 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.29 Cr..
For Reserves, as of Mar 2025, the value is 1.92 Cr.. The value appears strong and on an upward trend. It has increased from -5.08 Cr. (Mar 2024) to 1.92 Cr., marking an increase of 7.00 Cr..
For Borrowings, as of Mar 2025, the value is 3.20 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 7.71 Cr. (Mar 2024) to 3.20 Cr., marking a decrease of 4.51 Cr..
For Other Liabilities, as of Mar 2025, the value is 2.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.79 Cr. (Mar 2024) to 2.10 Cr., marking an increase of 0.31 Cr..
For Total Liabilities, as of Mar 2025, the value is 17.51 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.71 Cr. (Mar 2024) to 17.51 Cr., marking an increase of 2.80 Cr..
For Fixed Assets, as of Mar 2025, the value is 6.53 Cr.. The value appears to be declining and may need further review. It has decreased from 6.79 Cr. (Mar 2024) to 6.53 Cr., marking a decrease of 0.26 Cr..
For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Investments, as of Mar 2025, the value is 0.13 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 0.13 Cr., marking an increase of 0.13 Cr..
For Other Assets, as of Mar 2025, the value is 10.85 Cr.. The value appears strong and on an upward trend. It has increased from 7.92 Cr. (Mar 2024) to 10.85 Cr., marking an increase of 2.93 Cr..
For Total Assets, as of Mar 2025, the value is 17.51 Cr.. The value appears strong and on an upward trend. It has increased from 14.71 Cr. (Mar 2024) to 17.51 Cr., marking an increase of 2.80 Cr..

However, the Borrowings (3.20 Cr.) are higher than the Reserves (1.92 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Month	Mar 2012	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Cash from Operating Activity +	-0.02	-0.37	-1.29	-4.81	-3.39	-1.87	5.67	2.03	-0.01	1.05	1.88
Cash from Investing Activity +	0.08	-0.02	-10.14	-0.77	-1.97	0.24	-0.09	-0.51	0.16	0.14	0.07
Cash from Financing Activity +	-0.06	2.64	8.91	6.52	3.35	1.27	-2.17	-1.35	-0.94	-0.95	-0.99
Net Cash Flow	0.00	2.25	-2.52	0.94	-2.00	-0.35	3.41	0.17	-0.79	0.24	0.95

Free Cash Flow

Month	Mar 2012	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-0.02	-0.14	-2.85	-9.87	-15.24	-15.76	-15.63	-3.49	-2.47	-6.64	-8.89	0.33

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2011	Mar 2012	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days				43.22	29.30	38.22	26.01	40.80	83.87	59.07	61.94
Inventory Days				312.86	103.88	45.22	51.36	51.35	46.50	58.40	62.69
Days Payable				730.00	64.58	46.84	73.37	91.60	70.91	51.10	101.70
Cash Conversion Cycle				-373.92	68.61	36.60	4.00	0.55	59.46	66.37	22.93
Working Capital Days				-465.86	1.67	-2.39	-5.20	36.24	81.44	65.63	44.52
ROCE %	10.36%	0.00%	1.82%	-25.39%	-38.41%	-34.49%	-25.15%	19.77%	35.65%	2.01%	-15.87%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters	36.25%	36.25%	36.19%	34.55%	19.48%	19.47%	19.37%	18.90%	18.90%	18.72%	18.72%	18.55%
Public	63.75%	63.75%	63.81%	65.45%	80.53%	80.53%	80.64%	81.10%	81.10%	81.29%	81.28%	81.46%
No. of Shareholders	852	868	955	1,141	1,300	1,300	1,371	1,406	1,351	1,512	1,695	1,706

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25
FaceValue	10.00
Basic EPS (Rs.)	1.97
Diluted EPS (Rs.)	1.97
Cash EPS (Rs.)	3.46
Book Value[Excl.RevalReserv]/Share (Rs.)	11.82
Book Value[Incl.RevalReserv]/Share (Rs.)	11.82
Revenue From Operations / Share (Rs.)	21.37
PBDIT / Share (Rs.)	3.80
PBIT / Share (Rs.)	2.35
PBT / Share (Rs.)	2.01
Net Profit / Share (Rs.)	2.01
NP After MI And SOA / Share (Rs.)	1.97
PBDIT Margin (%)	17.79
PBIT Margin (%)	11.00
PBT Margin (%)	9.42
Net Profit Margin (%)	9.42
NP After MI And SOA Margin (%)	9.19
Return on Networth / Equity (%)	16.62
Return on Capital Employeed (%)	16.03
Return On Assets (%)	11.58
Long Term Debt / Equity (X)	0.09
Total Debt / Equity (X)	0.09
Current Ratio (X)	2.26
Quick Ratio (X)	2.05
Interest Coverage Ratio (X)	11.27
Interest Coverage Ratio (Post Tax) (X)	6.97
Enterprise Value (Cr.)	86.79
EV / Net Operating Revenue (X)	3.95
EV / EBITDA (X)	22.18
MarketCap / Net Operating Revenue (X)	3.99
Price / BV (X)	7.21
Price / Net Operating Revenue (X)	3.99
EarningsYield	0.02

After reviewing the key financial ratios for Aspira Pathlab & Diagnostics Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
For Basic EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Diluted EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Cash EPS (Rs.), as of Mar 25, the value is 3.46. This value is within the healthy range. No previous period data is available for comparison.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.82. No previous period data is available for comparison.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.82. No previous period data is available for comparison.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 21.37. No previous period data is available for comparison.
For PBDIT / Share (Rs.), as of Mar 25, the value is 3.80. This value is within the healthy range. No previous period data is available for comparison.
For PBIT / Share (Rs.), as of Mar 25, the value is 2.35. This value is within the healthy range. No previous period data is available for comparison.
For PBT / Share (Rs.), as of Mar 25, the value is 2.01. This value is within the healthy range. No previous period data is available for comparison.
For Net Profit / Share (Rs.), as of Mar 25, the value is 2.01. This value is within the healthy range. No previous period data is available for comparison.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 2. No previous period data is available for comparison.
For PBDIT Margin (%), as of Mar 25, the value is 17.79. This value is within the healthy range. No previous period data is available for comparison.
For PBIT Margin (%), as of Mar 25, the value is 11.00. This value is within the healthy range. No previous period data is available for comparison.
For PBT Margin (%), as of Mar 25, the value is 9.42. This value is below the healthy minimum of 10. No previous period data is available for comparison.
For Net Profit Margin (%), as of Mar 25, the value is 9.42. This value is within the healthy range. No previous period data is available for comparison.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.19. This value is within the healthy range. No previous period data is available for comparison.
For Return on Networth / Equity (%), as of Mar 25, the value is 16.62. This value is within the healthy range. No previous period data is available for comparison.
For Return on Capital Employeed (%), as of Mar 25, the value is 16.03. This value is within the healthy range. No previous period data is available for comparison.
For Return On Assets (%), as of Mar 25, the value is 11.58. This value is within the healthy range. No previous period data is available for comparison.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 0.2. No previous period data is available for comparison.
For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. No previous period data is available for comparison.
For Current Ratio (X), as of Mar 25, the value is 2.26. This value is within the healthy range. No previous period data is available for comparison.
For Quick Ratio (X), as of Mar 25, the value is 2.05. This value exceeds the healthy maximum of 2. No previous period data is available for comparison.
For Interest Coverage Ratio (X), as of Mar 25, the value is 11.27. This value is within the healthy range. No previous period data is available for comparison.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.97. This value is within the healthy range. No previous period data is available for comparison.
For Enterprise Value (Cr.), as of Mar 25, the value is 86.79. No previous period data is available for comparison.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.95. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
For EV / EBITDA (X), as of Mar 25, the value is 22.18. This value exceeds the healthy maximum of 15. No previous period data is available for comparison.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.99. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
For Price / BV (X), as of Mar 25, the value is 7.21. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.99. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. No previous period data is available for comparison.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Aspira Pathlab & Diagnostics Ltd as of July 27, 2025 is: 73.49

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of July 27, 2025, Aspira Pathlab & Diagnostics Ltd is Undervalued by 14.83% compared to the current share price 64.00

Intrinsic Value of Aspira Pathlab & Diagnostics Ltd as of July 27, 2025 is: 79.70

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of July 27, 2025, Aspira Pathlab & Diagnostics Ltd is Undervalued by 24.53% compared to the current share price 64.00

Last 5 Year EPS CAGR: 8.45%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a low average Working Capital Days of -20.33, which is a positive sign. The stock has a low average Cash Conversion Cycle of -9.62, which is a positive sign.	The stock has a low average ROCE of -5.81%, which may not be favorable. The company has higher borrowings (6.88) compared to reserves (-2.88), which may suggest financial risk. The company has not shown consistent growth in sales (8.80) and profit (-1.04).

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aspira Pathlab & Diagnostics Ltd:
1. Net Profit Margin: 9.42%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 16.03% (Industry Average ROCE: 16.02%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 16.62% (Industry Average ROE: 14.76%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 6.97
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 2.05
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 31.8 (Industry average Stock P/E: 125.77)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.09
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Aspira Pathlab & Diagnostics Ltd. is a Public Limited Listed company incorporated on 03/07/1973 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L85100MH1973PLC289209 and registration number is 289209. Currently Company is involved in the business activities of Other human health activities. Company's Total Operating Revenue is Rs. 22.00 Cr. and Equity Capital is Rs. 10.29 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Hospitals & Medical Services	Flat No.2, R.D. Shah Building, Mumbai Maharashtra 400086	info@aspiradiagnostics.com http://www.aspiradiagnostics.com

Management
Name	Position Held
Dr. Haseeb Drabu	Chairman & Ind.Director
Dr. Pankaj J Shah	Managing Director & CEO
Mr. Nikunj Mange	Executive Director
Mr. Manas Mengar	Independent Director
Mr. Avinash C Mahajan	Independent Director
Mrs. Mangala K Prabhu	Independent Director

FAQ

What is the intrinsic value of Aspira Pathlab & Diagnostics Ltd?

Aspira Pathlab & Diagnostics Ltd's intrinsic value (as of 27 July 2025) is 73.49 14.83% higher the current market price of 64.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 65.9 Cr. market cap, FY2025-2026 high/low of 107/29.2, reserves of 1.92 Cr, and liabilities of 17.51 Cr.

What is the Market Cap of Aspira Pathlab & Diagnostics Ltd?

The Market Cap of Aspira Pathlab & Diagnostics Ltd is 65.9 Cr..

What is the current Stock Price of Aspira Pathlab & Diagnostics Ltd as on 27 July 2025?

The current stock price of Aspira Pathlab & Diagnostics Ltd as on 27 July 2025 is 64.0.

What is the High / Low of Aspira Pathlab & Diagnostics Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Aspira Pathlab & Diagnostics Ltd stocks is ₹107/29.2.

What is the Stock P/E of Aspira Pathlab & Diagnostics Ltd?

The Stock P/E of Aspira Pathlab & Diagnostics Ltd is 31.8.

What is the Book Value of Aspira Pathlab & Diagnostics Ltd?

The Book Value of Aspira Pathlab & Diagnostics Ltd is 11.9.

What is the Dividend Yield of Aspira Pathlab & Diagnostics Ltd?

The Dividend Yield of Aspira Pathlab & Diagnostics Ltd is 0.00 %.

What is the ROCE of Aspira Pathlab & Diagnostics Ltd?

The ROCE of Aspira Pathlab & Diagnostics Ltd is 17.2 %.

What is the ROE of Aspira Pathlab & Diagnostics Ltd?

The ROE of Aspira Pathlab & Diagnostics Ltd is 23.8 %.

What is the Face Value of Aspira Pathlab & Diagnostics Ltd?

The Face Value of Aspira Pathlab & Diagnostics Ltd is 10.0.